Recent Finacing
Recent Raise
ChemomAb is a Tel Aviv biopharmaceutical developing monoclonal antibodies with dual mechanism targeting a key cellular-response protein to treat inflammatory and fibrotic diseases; lead asset in Phase 1 for NASH.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors